Top 10 most read GaBI Online articles in 2012

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Top 10 most read GaBI Online articles in 2012

INICIO/Noticias Farmacéuticas | Posted 24/01/2013 0 Post your comment

2012 was a busy year with lots of developments in biosimilars from regulatory guidelines to comparability issues. Biosimilars remain as the hot topic of the year for GaBI Online.

So what were the most viewed stories in GaBI Online 2012? To ensure that none of GaBI Online’s readers missed out on what happened in 2012, below is a list of the top 10 most read articles in 2012. Follow the links in the titles of each article to find out more…

Article title and link*
EMA responds to questions over biosimilar comparability
European uptake of biosimilars
Biosimilar terminology confusion
Abbott asks FDA to block adalimumab biosimilar
Top developments in biosimilars during 2011
Positioning of biosimilars: commodity versus differentiated
History of biosimilar monoclonal antibodies regulation in EU
EMA to accept biosimilar reference medicines from outside EEA
Biosimilar comparability debate continues
US$67 billion worth of biosimilar patents expiring before 2020
*arranged in top 10 order with the most read article listed first

From this ‘most read’ articles overview, the issue on biosimilar comparability (1st and 9th position) attracts a lot of interest and requires further input from experts. For this subject, GaBI Journal introduced a Special Issue on ‘Biosimilarity and Interchangeability’ with Professor Shein-Chung Chow as the Guest Editor.

Check out the first article titled ‘Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act’ by Professor Chow published in GaBI Journal, online first.

Biosimilar terminology (3rd position) requires proper clarification and definition. For this topic GaBI Journal publishes a full paper by Dr Robin Thorpe.

Another topic of interest is the European uptake of biosimilars (2nd position). Biosimilars entered the EU market in 2008 and uptake has been slow. What are the barriers affecting the uptake? How to resolve this? GaBI will cover this topic in 2013 via the educational series on ‘Biosimilars for healthcare professionals’. Click here to find out more.

If you are interested in contributing a research article in an area of interest to GaBI Journal, please send us your submission here.

GaBI’s mission – Building trust in cost-effective treatments

Editor’s comment
What do you think about GaBI Online providing overviews of this type? Please feel free to share your thoughts via email or in the comments section below. What other overviews would you like to see?

Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.